Method for propagating adenoviral vectors encoding inhibitory gene products

Abstract

The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector.

1 . A method of propagating an adenoviral vector, which method comprises:
 (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and   (b) contacting the cell with an adenoviral vector having an adenoviral genome comprising a heterologous nucleic acid sequence encoding a protein that is toxic to the cell, wherein the heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), so as to transfect the cell with the adenoviral vector,   wherein the nucleic acid sequence encoding tetR is expressed to produce tetR, expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, and the adenoviral vector is propagated.   
     
     
         2 . The method of  claim 1 , wherein the adenoviral vector is replication-deficient. 
     
     
         3 . The method of  claim 2 , wherein the adenoviral vector requires, at most, complementation of the E1 region of the adenoviral genome for replication. 
     
     
         4 . The method of  claim 2 , wherein the adenoviral vector requires, at most, complementation of the E4 region of the adenoviral genome for replication. 
     
     
         5 . The method of  claim 2 , wherein the adenoviral vector has an adenoviral genome devoid of all of the E1 region and at least a portion of the E4 region, and the adenoviral vector requires, at most, complementation of the E1 and E4 regions of the adenoviral genome for replication. 
     
     
         6 . The method of  claim 1  wherein the adenoviral vector lacks all or part of the E3 region of the adenoviral genome. 
     
     
         7 . The method of  claim 1 , wherein the adenoviral genome is a subgroup C adenoviral genome. 
     
     
         8 . The method of  claim 1 , wherein the adenoviral genome is a non-subgroup C adenoviral genome. 
     
     
         9 . The method of  claim 1 , wherein the heterologous nucleic acid sequence encodes an env, gag, or pol protein from clades A, B, or C of a human immunodeficiency virus (HIV), or a fusion protein comprising any of the foregoing. 
     
     
         10 . The method of  claim 1 , wherein the heterologous nucleic acid sequence encodes an E protein, an M protein, or a spike protein of a severe acute respiratory syndrome (SARS) virus. 
     
     
         11 . The method of  claim 1 , wherein the heterologous nucleic acid sequence encodes a transforming growth factor β (TGFβ), an antibiotic, a malaria protein, or a nitric oxide synthase. 
     
     
         12 . The method of  claim 1 , wherein the cell comprises a cellular genome into the nuclear genome of which is inserted the open reading frame-6 (ORF-6) and no other open reading frame of the E4 region of an adenoviral genome operably linked to a promoter, and which cell line complements in trans an adenoviral vector comprising an adenoviral genome having a deletion of the E1 and E4 regions of the adenoviral genome. 
     
     
         13 . The method of  claim 12 , wherein the ORF-6 of the E4 region of the adenoviral genome is operably linked to an inducible promoter. 
     
     
         14 . A system comprising:
 (a) a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), which can be expressed to produce tetR, and   (b) an adenoviral vector having an adenoviral genome comprising a heterologous nucleic acid sequence encoding a protein that is toxic to the cell, wherein the heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and wherein the adenoviral vector can transfect the cell and be propagated in the cell.   
     
     
         15 . The system of  claim 14 , wherein the adenoviral vector is replication-deficient. 
     
     
         16 . The system of  claim 15 , wherein the adenoviral vector requires, at most, complementation of the E1 region of the adenoviral genome for replication. 
     
     
         17 . The system of  claim 15  or  claim 16 , wherein the adenoviral vector requires, at most, complementation of the E4 region of the adenoviral genome for replication. 
     
     
         18 . The system of  claim 15 , wherein the adenoviral vector has an adenoviral genome devoid of all of the E1 region and at least a portion of the E4 region, and the adenoviral vector requires, at most, complementation of the E1 and E4 regions of the adenoviral genome for replication. 
     
     
         19 . The system of  claim 14 , wherein the adenoviral vector lacks all or part of the E3 region of the adenoviral genome. 
     
     
         20 . The system of  claim 14 , wherein the adenoviral genome is a subgroup C adenoviral genome. 
     
     
         21 . The system of  claim 14 , wherein the adenoviral genome is a non-subgroup C adenoviral genome. 
     
     
         22 . The system  claim 14 , wherein the heterologous nucleic acid sequence encodes an env, gag, or pol protein from clades A, B, or C of a human immunodeficiency virus (HIV), or a fusion protein comprising any of the foregoing. 
     
     
         23 . The system of  claim 14 , wherein the heterologous nucleic acid sequence encodes an E protein, an M protein, or a spike protein of a severe acute respiratory syndrome (SARS) virus. 
     
     
         24 . The system of  claim 14 , wherein the heterologous nucleic acid sequence encodes a transforming growth factor β (TGFβ), an antibiotic, a malaria protein, or a nitric oxide synthase. 
     
     
         25 . The system of  claim 14 , wherein the cell comprises a cellular genome into the nuclear genome of which is inserted the open reading frame-6 (ORF-6) and no other open reading frame of the E4 region of an adenoviral genome operably linked to a promoter, and which cell line complements in trans an adenoviral vector comprising an adenoviral genome having a deletion of the E1 and E4 regions of the adenoviral genome. 
     
     
         26 . The system of  claim 25 , wherein the ORF-6 of the E4 region of the adenoviral genome is operably linked to an inducible promoter. 
     
     
         27 . The method of  claim 1 , wherein the adenoviral vector is replication-competent. 
     
     
         28 . The method of  claim 1 , wherein the heterologous nucleic acid sequence encodes protein 1A, 1B, 1C, 1D, 2A, 2B, 2C, 3A, 3B, 3C, or 3D of a foot-and-mouth disease virus (FMD). 
     
     
         29 . The system of  claim 16 , wherein the adenoviral vector is replication-competent. 
     
     
         31 . The system of  claim 16 , wherein the heterologous nucleic acid sequence encodes protein 1A, 1B, 1C, 1D, 2A, 2B, 2C, 3A, 3B, 3C, or 3D of a foot-and-mouth disease virus (FMD).